OnMune is a precision medicine startup building AI-driven patient immune-digital twins to accelerate evidence-based drug repurposing in oncology and immune-mediated diseases. We integrate clinical, molecular, and real-world data into a unified representation of each patient to support more personalized, faster, and cost‑effective treatment decisions.

By leveraging advanced machine learning and systems biology, our platform helps identify repurposable drugs and rational combinations tailored to individual disease biology, with the goal of improving outcomes while reducing development time and cost. Our vision is to make data‑driven, personalized treatment selection accessible in routine clinical practice, starting with oncology and autoimmune indications.

OnMune collaborates with clinicians, hospitals, and industry partners to validate its approach in real‑world settings and to design studies that bridge the gap between algorithmic predictions and clinical utility. We are currently at an early stage, building our technology, scientific partnerships, and regulatory strategy, while engaging with investors and collaborators who share our commitment to transforming precision medicine.

Focus areas include:
Immune-Digital Twins integrating multi‑modal patient data
AI‑guided drug repurposing and treatment prioritization
Oncology and immune‑mediated indications
Clinically actionable, explainable insights for decision support

If you are an oncologist, immunologist, clinical researcher, or industry partner interested in AI‑enabled precision medicine, we would be glad to connect.

OnMune

Org chart

Teams

Offices

OnMune

Org chart

Teams

Offices

Related companies